Form 4: ANI Pharmaceuticals Executive Christopher Mutz Reports Stock Transaction

Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports the disposal of 2,110 shares for tax purposes following the vesting of restricted stock.

Summary

• On March 7, 2024, Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reported a transaction involving the company's common stock.
• A total of 2,110 shares were disposed of at a price of $66.71 per share.
• This transaction was related to the withholding of shares for tax purposes in connection with the vesting of 6,476 shares of restricted stock.
• Following the transaction, Mutz directly owns 85,277 shares of ANI Pharmaceuticals.
• The transaction was executed under Rule 16(b)-3, exempting it from certain short-swing profit rules.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a routine stock transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding insider transactions to investors.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine disposal of shares for tax purposes.

Key Dates